Literature DB >> 9444574

Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics.

A E Evins1, E T Amico, V Shih, D C Goff.   

Abstract

To examine whether serum excitatory amino acid concentrations change with clozapine treatment and whether these changes correlate with improvement in negative symptoms, serum excitatory amino acids were measured and clinical scales administered in seven subjects with schizophrenia before and after switching from conventional neuroleptics to clozapine. Clozapine treatment was associated with increased serum glutamate and aspartate concentrations. Clinical improvement was negatively correlated with baseline glycine concentrations. These results support the hypothesis that clozapine acts at least in part by increasing glutamatergic activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444574     DOI: 10.1007/BF01291892

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  19 in total

1.  Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals.

Authors:  E H McGale; I F Pye; C Stonier; E C Hutchinson; G M Aber
Journal:  J Neurochem       Date:  1977-08       Impact factor: 5.372

2.  Glutamate and glutamine in cerebrospinal fluid and serum from healthy volunteers--analytical aspects.

Authors:  G Alfredsson; F A Wiesel; M Lindberg
Journal:  J Chromatogr       Date:  1988-02-26

3.  Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity.

Authors:  N B Farber; M T Price; J Labruyere; J Nemnich; H St Peter; D F Wozniak; J W Olney
Journal:  Biol Psychiatry       Date:  1993 Jul 1-15       Impact factor: 13.382

Review 4.  The glutamatergic dysfunction hypothesis for schizophrenia.

Authors:  J T Coyle
Journal:  Harv Rev Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.732

5.  Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.

Authors:  V P Bakshi; N R Swerdlow; M A Geyer
Journal:  J Pharmacol Exp Ther       Date:  1994-11       Impact factor: 4.030

6.  Brain region effects of clozapine on amino acid and monoamine transmission.

Authors:  B K Yamamoto; E A Pehek; H Y Meltzer
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

7.  Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers.

Authors:  G Alfredsson; F A Wiesel; A Tylec
Journal:  Biol Psychiatry       Date:  1988-04-01       Impact factor: 13.382

8.  MK-801-induced stereotypy and its antagonism by neuroleptic drugs.

Authors:  P I Tiedtke; C Bischoff; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1990

9.  Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.

Authors:  D C Goff; G Tsai; D S Manoach; J T Coyle
Journal:  Am J Psychiatry       Date:  1995-08       Impact factor: 18.112

10.  Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors.

Authors:  R Corbett; F Camacho; A T Woods; L L Kerman; R J Fishkin; K Brooks; R W Dunn
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

View more
  15 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 2.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 3.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

4.  Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.

Authors:  Danielle L Taylor; Arun K Tiwari; Jeffrey A Lieberman; Steven G Potkin; Herbert Y Meltzer; Joanne Knight; Gary Remington; Daniel J Müller; James L Kennedy
Journal:  Mol Neuropsychiatry       Date:  2016-10-12

Review 5.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

6.  Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex.

Authors:  Constance M Moore; Joseph Biederman; Janet Wozniak; Eric Mick; Megan Aleardi; Megan Wardrop; Meghan Dougherty; Terri Harpold; Paul Hammerness; Edin Randall; In Kyoon Lyoo; Perry F Renshaw
Journal:  J Affect Disord       Date:  2006-09-26       Impact factor: 4.839

Review 7.  Managing Negative Symptoms of Schizophrenia: How Far Have We Come?

Authors:  Joshua T Kantrowitz
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 8.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

9.  Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms.

Authors:  Jun Cai; Wen Zhang; Zhenghui Yi; Weihong Lu; Zhiguo Wu; Jun Chen; Shunying Yu; Yiru Fang; Chen Zhang
Journal:  Psychopharmacology (Berl)       Date:  2013-05-10       Impact factor: 4.530

10.  Peripheral amino Acid levels in schizophrenia and antipsychotic treatment.

Authors:  Vincenzo De Luca; Emanuela Viggiano; Giovanni Messina; Alessandro Viggiano; Carol Borlido; Andrea Viggiano; Marcellino Monda
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.